Feb
14
2025
Recovery Navigator Program
The Recovery Navigator Program (RNP) is a statewide effort, in partnership with behavioral health administrative organizations (BH-ASOs) to provide community-based outreach, intake, assessment, and connection to services.
On this page
About RNP
RNP supports services for youth and adults with substance use disorder (SUD), including individuals with co-occurring SUDs, mental health conditions, and others who are referred from community sources.
Read the goals and directions for RNP in RCW 71.24.115.
Learn more
- Read the 2025 Recovery Navigator uniform program standards.
- Read the 2021 Recovery Navigator uniform program standards.
- Read the Recovery Navigator program fact sheet.
- View the Recovery Navigator program provider directory.
Data dashboard
Recovery Navigator programs are required to submit quarterly reports to the Health Care Authority (HCA) with data that summarizes the services provided by each regional program.
Data can include:
- The number of people referred to the program and for what reasons
- The number of outreach attempts
- The number of individuals enrolled in light or intensive case management
- Demographic distributions of the populations served
Balloon angioplasty and stenting for lower extremity peripheral arterial disease
Peripheral artery disease (PAD) is a cardiovascular condition that most often develops as a result of atherosclerotic plaque buildup that reduces blood flow to the peripheral arteries. PAD most commonly occurs in the lower extremities and may affect three major arterial segments which supply blood to the legs and feet. Endovascular intervention, including procedures such as angioplasty and stent placement, is commonly used in the management of lower extremity PAD.
Status: Public comment open
Why is this topic being reviewed?
Endovascular intervention, including procedures such as angioplasty and stent placement, is commonly used in the management of lower extremity peripheral arterial disease. This topic was selected for review based on concerns regarding safety, efficacy and cost.
Primary criteria ranking
- Safety = Medium
- Efficacy = Medium
- Cost = High
Documentation
| Type | Materials |
|---|---|
| Assessment (2025) |
Assessment timeline
- Draft key questions published: February 6, 2025
- Public comment period: February 6 to February 19, 2025
- Final key questions: March 13, 2025
- Draft report published: June 26, 2025
- Public comment period: June 26 to July 25, 2025
- Final report published: August 20, 2025
- HTCC public meeting: November 21, 2025
- Draft findings and decision published: December 2, 2025
- Public comment period: December 2 to December 16, 2025
- Final findings and decision published: March 20, 2026
All future dates are estimates and subject to change.